Plasma proteomics identifies insulin resistance signatures predictive of cardiometabolic disease risk
Abstract Insulin resistance drives cardiometabolic disease, yet its molecular signatures and tissue origins remain incompletely characterized. Here we define a circulating protein signature that enables scalable assessment of insulin sensitivity. We applied multiworkflow proteomics to plasma from 161 individuals spanning the insulin sensitivity spectrum defined by the hyperinsulinaemic–euglycaemic clamp and identified 488 proteins associated with insulin sensitivity, capturing contributions from liver, adipose tissue and immune cells. A subset of these proteins shifted towards a more insulin-sensitive profile following an exercise intervention in men. We further developed a model combining 13 proteins, including IGFBP1, LEP, GDF15, PON3 and LDLR, with clinical variables (sex, HbA1c and the triglyceride-to-high-density lipoprotein cholesterol ratio) to predict insulin sensitivity ( R 2 = 0.67). In ~20,000 UK Biobank participants, the model outperformed the triglyceride-to-high-density lipoprotein cholesterol ratio in predicting type 2 diabetes (concordance index, 0.86 versus 0.74) and, unlike HbA1c, predicted hepatic, renal, cardiovascular and respiratory disease. In an independent cohort of 1,700 individuals, the model also showed greater predictive utility than fasting insulin resistance indices, including the homeostatic model assessment of insulin resistance. Together, these findings establish a tissue-resolved plasma proteomic framework for characterizing insulin resistance and provide a scalable approach to precision cardiometabolic risk stratification.
Authors
- Juleen Rae Zierath (ORCID: https://orcid.org/0000-0001-6891-7497)
- Ruth J. F. Loos (ORCID: https://orcid.org/0000-0002-8532-5087)
- Nigel Kurgan (ORCID: https://orcid.org/0000-0002-5011-0297)
- Mikael Rydén (ORCID: https://orcid.org/0000-0003-4785-1876)
- Kurt Højlund (ORCID: https://orcid.org/0000-0002-0891-4224)
- Jordi Merino (ORCID: https://orcid.org/0000-0001-8312-1438)
- Naixin Zhang (ORCID: https://orcid.org/0000-0001-6683-417X)
- Paola Pisano
- Marta Guasch‐Ferré (ORCID: https://orcid.org/0000-0001-8525-1404)
- Anna Krook (ORCID: https://orcid.org/0000-0002-0891-0258)
- Michael Wierer (ORCID: https://orcid.org/0000-0002-0356-5571)
- Simon Rasmussen (ORCID: https://orcid.org/0000-0001-6323-9041)
- Martin Eisemann de Almeida (ORCID: https://orcid.org/0000-0003-1794-6137)
- Atul S. Deshmukh (ORCID: https://orcid.org/0000-0002-2278-1843)
- Niels Ørtenblad (ORCID: https://orcid.org/0000-0001-9060-4139)
- Farina L. Schlabs (ORCID: https://orcid.org/0009-0006-2614-1620)
- Zhe Wang (ORCID: https://orcid.org/0000-0002-8046-4969)
- Maria Houborg Petersen (ORCID: https://orcid.org/0000-0002-9502-1618)
- Lisa Ottander (ORCID: https://orcid.org/0009-0007-3211-7878)
- Jeppe Kjærgaard Northcote*
- Justs F. Gräf (ORCID: https://orcid.org/0000-0002-8945-5903)
- Mafalda Da Cruz Custódio
- Roelof A.J. Smit
- Tuomas O. Kilpeläinen
- Jacob Stidsen
Institutions
- Broad Institute (US)
- University of Copenhagen (DK)
- Karolinska University Hospital (SE)
- Harvard University (US)
- University of British Columbia (CA)
- University of Southern Denmark (DK)
- Odense University Hospital (DK)
- Karolinska Institutet (SE)
- University of Alabama at Birmingham (US)
- Novo Nordisk Foundation Center for Basic Metabolic Research (DK)
- Steno Diabetes Center Copenhagen (DK)
- Massachusetts Institute of Technology (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Nature Metabolism
- Published
- 2026-11-16
- DOI
- https://doi.org/10.1038/s42255-026-01662-1
- Primary Topic
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Hjerteforeningen
- Lundbeckfonden
- Karolinska Institutet
- Knut och Alice Wallenbergs Stiftelse
- Novo Nordisk
- Odense Universitetshospital
- Vetenskapsrådet
- Syddansk Universitet
- Copenhagen Graduate School for Nanoscience and Nanotechnology
- Faculty of Health and Medical Sciences, University of Western Australia
- Novo Nordisk Fonden
- Novo Nordisk Foundation Center for Basic Metabolic Research
- H. Lundbeck A/S
- Det Sundhedsvidenskabelige Fakultet, Københavns Universitet
- National Heart, Lung, and Blood Institute